[{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Global Blood Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
